200 Arsenal Yards Boulevard
Suite 210
Watertown, MA 02472
United States
617 758 8672
https://www.sqzbiotech.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 53
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Howard Bernstein M.D., Ph.D. | Interim CEO & Director | 552.14k | N/A | 1957 |
Mr. Lawrence J. Knopf Esq. | General Counsel & Secretary | 512.38k | N/A | 1962 |
Dr. Marshelle Smith Warren M.D. | Chief Medical Officer | 476.27k | N/A | 1964 |
Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder & Member of Scientific Advisory Board | N/A | N/A | 1949 |
Mr. Richard V. Capasso CPA | Chief Accounting Officer | N/A | N/A | 1962 |
Mr. David First | Chief People Officer | N/A | N/A | 1964 |
Ipsita Roymoulik Ph.D. | Senior Vice President of CMC & QUALITY | N/A | N/A | N/A |
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
SQZ Biotechnologies Company’s ISS Governance QualityScore as of June 1, 2024 is 8. The pillar scores are Audit: 4; Board: 7; Shareholder Rights: 9; Compensation: 9.